title: Daclizumab in treatment of multiple sclerosis patients.
abstract: BACKGROUND
  Daclizumab is a humanized monoclonal antibody (mAb) that blocks the interleukin-2 receptor alpha subunit (IL-2R-alpha chain; CD25) expressed on activated T cells leading to the inhibition of T-cell expansion, thus strongly reduces brain inflammation in patients with multiple sclerosis (MS). Another mechanism is significant expansion of CD56 (bright) natural killer (NK) cells that in turn inhibit T-cell survival.
  
  
  OBJECTIVE
  At the Partners MS center, we have been using Daclizumab in an open-label fashion in patients who fail first line therapy or non-standard immunosuppressive treatment. Our aim was to assess its safety and tolerability in our patient population.
authors.affiliation: Partners MS Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. eman_c5@yahoo.com
authors.forename: E N
authors.initials: EN
authors.lastname: Ali
authors.forename: B C
authors.initials: BC
authors.lastname: Healy
authors.forename: L A
authors.initials: LA
authors.lastname: Stazzone
authors.forename: B A
authors.initials: BA
authors.lastname: Brown
authors.forename: H L
authors.initials: HL
authors.lastname: Weiner
authors.forename: S J
authors.initials: SJ
authors.lastname: Khoury
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000077561:Daclizumab; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage* / Q000009:adverse effects; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D020528:Multiple Sclerosis, Chronic Progressive / Q000188:drug therapy*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000077561:Daclizumab